Zura Bio’s (ZURA) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Zura Bio (NASDAQ:ZURA) in a report issued on Tuesday morning,Benzinga reports. They currently have a $5.00 price objective on the stock.

Other equities research analysts have also issued reports about the stock. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Leerink Partners started coverage on Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective for the company. Chardan Capital cut their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Finally, Piper Sandler reissued an “overweight” rating and issued a $26.00 price objective on shares of Zura Bio in a research report on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Zura Bio presently has a consensus rating of “Buy” and a consensus target price of $15.80.

Zura Bio Price Performance

Zura Bio stock opened at $2.32 on Tuesday. The firm has a 50 day simple moving average of $3.52 and a 200-day simple moving average of $3.67. Zura Bio has a 1-year low of $2.00 and a 1-year high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Equities analysts forecast that Zura Bio will post -0.65 EPS for the current year.

Insider Buying and Selling

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 22.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. acquired a new position in Zura Bio in the second quarter valued at $8,446,000. Armistice Capital LLC grew its holdings in Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after buying an additional 876,000 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of Zura Bio during the 3rd quarter valued at about $71,000. Braidwell LP purchased a new position in shares of Zura Bio during the 3rd quarter worth about $10,040,000. Finally, Great Point Partners LLC boosted its position in shares of Zura Bio by 68.3% in the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after acquiring an additional 1,884,501 shares during the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.